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ence, signiﬁcance, and management of minimal residual
disease (MRD) in acute myelogeous leukemia (AML) are
complex, controversial, andnot clearlydeﬁned [1,2]. AML isnot
a single disease, but rather a heterogeneous collection of
diseases with characteristic recurrent cytogenetic and/or
molecular genetic abnormalities that lead to an arrest of
myeloid differentiation. Although many of the mutations,
duplications, and translocations that contribute to the devel-
opment of AML are known, some patients have a normal
karyotypeandnoroutinely identiﬁablegeneticaberration.This
suggests that the full spectrumofgeneticandepigenetic factors
involved in the pathogenesis of AML has yet to be discovered.
Complete remission (CR) in AML is deﬁned as a bone
marrow with <5% myeloblasts by morphology after induc-
tion chemotherapy and restoration of normal hematopoiesis,
as demonstrated by an absolute neutrophil count >1000/mL
and a platelet count >100,000/mL [3]. It is intuitive that
cytogenetic, molecular genetic, or immunophenotypic
evidence of residual AML in a bone marrow in morphologic
CR, whether discovered by traditional cytogenetics, ﬂuores-
cence in situ hybridization, PCR, or ﬂow cytometry, portends
a poor postremission course. In some clinicians, this intuition
now inﬂuences clinical decisions.
In medicine, intuition may lead us astray, however. The
questions raisedby thepresenceof apparentMRDareeasier to
recount than the answers. How do we deﬁne MRD? Is it
deﬁned by persistent cytogenetic abnormalities, molecular
genetic abnormalities, immunophenotyping, or some combi-
nation of modalities? What are the sensitivities and speciﬁc-
ities of the various assays for MRD? Is there a level below
which the presence of MRD is insigniﬁcant? Should assess-
ment for MRD be done on count recovery after induction,
before consolidation therapy, between cycles of consolidation
therapy (if given as chemotherapy), or after consolidation
therapy?Does thepresenceofMRDpredict relapse inall of the
many single and cooperating cytogenetic and molecular
genetic abnormalities that produce an AML phenotype? And,Financial disclosure: See Acknowledgments on page 171.
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http://dx.doi.org/10.1016/j.bbmt.2012.12.009most importantly, how should the presence of MRD affect
clinical practice? Should the presence of MRD after induction
encourage clinicians to achieve a MRD-free state before
proceeding to consolidation? How does the presence of MRD
affect decisions regarding the timing of transplantation?
In this issue of Biology of Blood and Marrow Trans-
plantation, Oran and colleagues begin to address the thorny
issues surrounding MRD [4]. Mining the M.D. Anderson
Cancer Center clinical database, they investigated the pres-
ence and clinical impact of an abnormal karyotype, detected
by traditional metaphase cytogenetics before allogeneic cell
transplantation for AML in ﬁrst morphological CR. Using
multivariate regression analysis, they identiﬁed risk groups
based on cytogenetic data at diagnosis and the persistence
of cytogenetic abnormalities after CR but before trans-
plantation. Patients with unfavorable cytogenetics at diag-
nosis in a morphological CR but persistent cytogenetic
aberrations at transplantation have decreased leukemia-free
survival and an increased cumulative incidence of relapse
compared with patients with a normal karyotype at the time
of transplantation. Interestingly, there was no statistically
signiﬁcant difference in overall survival between these 2
groups of patients, suggesting that the presence of cytoge-
netic abnormalities at the time of transplantation should not
necessarily lead to postponement of the allograft.
The analysis of Oran et al. has several limitations. Their
study was a retrospective review of patients in ﬁrst CR who
had a matched donor (sibling or unrelated) available for
transplantation. Mismatched donors and haploidentical
transplantations were not included in the analysis. All of
the patients received a busulfan and ﬂudarabine-based
conditioning regimen, raising the question of whether other
conditioning regimens would be more effective for patients
with an abnormal karyotype at the time of transplantation.
MRD was assessed by traditional metaphase cytogenetics
rather than the more sensitive ﬂuorescence in situ hybrid-
ization testing or molecular diagnostics. We are not told how
many patients in each group had a monosomal karyotype,
which is associated with particularly poor outcomes [5]. In
addition, it would be of interest to investigate whether the
use of hypomethylating agents as maintenance therapy
posttransplantation can abrogate the risk imposed by the
presence of MRD. Finally, the number of patients with an
abnormal karyotype at the time of transplantationwas small,
as reﬂected in the wide conﬁdence intervals seen on the
univariate and multivariate analyses.
Despite these limitations, Oran and colleagues provide
further retrospective evidence that patients with cytogeneti-
cally unfavorable AMLwithMRD at the time of transplantation
as assessed by traditional metaphase cytogenetics are at
increased risk for relapse and decreased leukemia-free
